Repeat: Treatment.com AI and Aiyibotong collaborate to explore commercial opportunities for Clinical Decision Support in China and Far East
April 01, 2025 08:00 ET | Source: Treatment.com AI Inc. Market for…
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinsons Disease at AD/PD 2025
April 01, 2025 08:15 ET | Source: Cerevance, Inc. Solengepras showed evidence…
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiologys Annual Scientific Session 2025
− New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Transforming Wellness: Abundant Health Introduces RENEW Protocols for Lasting Relief
Davenport, Iowa, March 28, 2025 (GLOBE NEWSWIRE) -- Abundant Health Physical Medicine,…
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts,…
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 24, 2025 16:20 ET | Source: Bolt Biotherapeutics, Inc. BDC-4182 on…
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver…
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class…